CA2102447A1 - Cyclopeptides - Google Patents
CyclopeptidesInfo
- Publication number
- CA2102447A1 CA2102447A1 CA002102447A CA2102447A CA2102447A1 CA 2102447 A1 CA2102447 A1 CA 2102447A1 CA 002102447 A CA002102447 A CA 002102447A CA 2102447 A CA2102447 A CA 2102447A CA 2102447 A1 CA2102447 A1 CA 2102447A1
- Authority
- CA
- Canada
- Prior art keywords
- asp
- gly
- arg
- ala
- cyclopeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001189 Cyclic Peptides Human genes 0.000 title abstract 2
- 108010069514 Cyclic Peptides Proteins 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to novel cyclopeptides of the formula I cyclo-(A-B-C-D-Arg) I in which A and B are each independently of one another Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val, C is Asp or Asp (O-C1-4-alkyl) and D is Gly or Ala, at least two of the amino acid radicals stated being present in the D-form, and their salts. These compounds act as integrin inhibitors and can be used in particular for the prophylaxis and treatment of disorders of the circulation and in tumour therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4237456A DE4237456A1 (en) | 1992-11-06 | 1992-11-06 | cyclopeptides |
DEP4237456.1 | 1992-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2102447A1 true CA2102447A1 (en) | 1994-05-07 |
CA2102447C CA2102447C (en) | 2007-04-10 |
Family
ID=6472232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002102447A Expired - Lifetime CA2102447C (en) | 1992-11-06 | 1993-11-04 | Cyclopeptides |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0596350B1 (en) |
JP (1) | JP3681764B2 (en) |
KR (1) | KR100238894B1 (en) |
CN (1) | CN1038751C (en) |
AT (1) | ATE154037T1 (en) |
AU (1) | AU666586B2 (en) |
CA (1) | CA2102447C (en) |
CZ (1) | CZ286170B6 (en) |
DE (2) | DE4237456A1 (en) |
DK (1) | DK0596350T3 (en) |
ES (1) | ES2105041T3 (en) |
GR (1) | GR3024550T3 (en) |
HU (1) | HU215600B (en) |
MX (1) | MX9306885A (en) |
NO (1) | NO309864B1 (en) |
PL (1) | PL177772B1 (en) |
RU (1) | RU2129563C1 (en) |
SK (1) | SK280597B6 (en) |
TW (1) | TW340849B (en) |
UA (1) | UA43822C2 (en) |
ZA (1) | ZA938281B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11975041B2 (en) * | 2017-11-20 | 2024-05-07 | Novmetapharma Co., Ltd. | Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816449A (en) * | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
-
1992
- 1992-11-06 DE DE4237456A patent/DE4237456A1/en not_active Withdrawn
-
1993
- 1993-10-23 DE DE59306654T patent/DE59306654D1/en not_active Expired - Lifetime
- 1993-10-23 EP EP93117204A patent/EP0596350B1/en not_active Expired - Lifetime
- 1993-10-23 ES ES93117204T patent/ES2105041T3/en not_active Expired - Lifetime
- 1993-10-23 AT AT93117204T patent/ATE154037T1/en active
- 1993-10-23 DK DK93117204.3T patent/DK0596350T3/en active
- 1993-10-29 KR KR1019930022666A patent/KR100238894B1/en not_active IP Right Cessation
- 1993-10-29 UA UA93002450A patent/UA43822C2/en unknown
- 1993-11-01 AU AU50399/93A patent/AU666586B2/en not_active Expired
- 1993-11-02 SK SK1217-93A patent/SK280597B6/en not_active IP Right Cessation
- 1993-11-04 CA CA002102447A patent/CA2102447C/en not_active Expired - Lifetime
- 1993-11-04 CZ CZ19932352A patent/CZ286170B6/en not_active IP Right Cessation
- 1993-11-04 TW TW082109233A patent/TW340849B/en active
- 1993-11-04 RU RU93050068A patent/RU2129563C1/en active
- 1993-11-04 MX MX9306885A patent/MX9306885A/en unknown
- 1993-11-04 PL PL93300935A patent/PL177772B1/en unknown
- 1993-11-05 HU HU9303149A patent/HU215600B/en unknown
- 1993-11-05 ZA ZA938281A patent/ZA938281B/en unknown
- 1993-11-05 NO NO934003A patent/NO309864B1/en unknown
- 1993-11-05 JP JP30962593A patent/JP3681764B2/en not_active Expired - Lifetime
- 1993-11-05 CN CN93114224A patent/CN1038751C/en not_active Expired - Lifetime
-
1997
- 1997-08-27 GR GR970402189T patent/GR3024550T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL177772B1 (en) | 2000-01-31 |
SK280597B6 (en) | 2000-04-10 |
EP0596350A1 (en) | 1994-05-11 |
RU2129563C1 (en) | 1999-04-27 |
PL300935A1 (en) | 1994-05-16 |
JP3681764B2 (en) | 2005-08-10 |
KR940011479A (en) | 1994-06-21 |
TW340849B (en) | 1998-09-21 |
ES2105041T3 (en) | 1997-10-16 |
DE4237456A1 (en) | 1994-05-11 |
ATE154037T1 (en) | 1997-06-15 |
NO934003D0 (en) | 1993-11-05 |
GR3024550T3 (en) | 1997-12-31 |
EP0596350B1 (en) | 1997-06-04 |
UA43822C2 (en) | 2002-01-15 |
AU5039993A (en) | 1994-05-19 |
CZ286170B6 (en) | 2000-02-16 |
NO309864B1 (en) | 2001-04-09 |
SK121793A3 (en) | 1995-06-07 |
HU215600B (en) | 1999-01-28 |
AU666586B2 (en) | 1996-02-15 |
CA2102447C (en) | 2007-04-10 |
HUT68321A (en) | 1995-06-28 |
DK0596350T3 (en) | 1997-12-29 |
CN1093090A (en) | 1994-10-05 |
KR100238894B1 (en) | 2000-01-15 |
CZ235293A3 (en) | 1994-07-13 |
CN1038751C (en) | 1998-06-17 |
NO934003L (en) | 1994-05-09 |
DE59306654D1 (en) | 1997-07-10 |
MX9306885A (en) | 1995-01-31 |
ZA938281B (en) | 1994-06-07 |
JPH0892282A (en) | 1996-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2120303A1 (en) | Cyclic adhesion inhibitors | |
NZ248377A (en) | Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors | |
IL104314A0 (en) | Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them | |
HK1160778A1 (en) | Pharmaceutical composition comprising an analgesic peptide | |
CA2148194A1 (en) | Cyclopeptides of the formula i | |
CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
NO941151L (en) | Linear adhesion inhibitors | |
CA2002924A1 (en) | Anti-Thrombins | |
GR3015888T3 (en) | Peptides for treatment. | |
CA2102606A1 (en) | Compositions for the treatment of chronic fatigue syndrome | |
HUP0003357A2 (en) | Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use | |
CA2096933A1 (en) | Compounds and compositions which inhibit bone resorption | |
CA2102447A1 (en) | Cyclopeptides | |
DE3569541D1 (en) | Pharmacologically active peptides | |
CA2290739A1 (en) | New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy | |
HK1013622A1 (en) | Pharmaceutical lysine-containing polypeptide compositions and the use thereof | |
RU95120588A (en) | CYCLOGEXAEPEPTIDES, THEIR MIXTURES, METHOD FOR PRODUCING AND USING THEM | |
EP0248231A3 (en) | Pharmacologically active peptides | |
NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
KR950704358A (en) | Cathepsin L specific inhibitory polypeptide | |
IL115825A0 (en) | Therapeutic protein | |
RU93050068A (en) | CYCLOPEPTIDES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND METHOD OF THEIR PRODUCTION, METHOD OF TREATMENT | |
EP0621789A4 (en) | Pharmaceutical pentapeptide compositions and methods of use thereof. | |
RU94036002A (en) | Protease inhibitor, dna, vector, cell, method of inhibitor preparing, pharmaceutical composition | |
AU2002238532A1 (en) | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20131104 |